Literature DB >> 12407508

Metastatic melanoma: chemotherapy.

Emilio Bajetta1, Michele Del Vecchio, Chantal Bernard-Marty, Milena Vitali, Roberto Buzzoni, Olivier Rixe, Paola Nova, Stefania Aglione, Sophie Taillibert, David Khayat.   

Abstract

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of 47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural history, melanoma is cured in most cases by surgery, but once the metastatic phase develops, it is almost always fatal. The treatment of metastatic melanoma remains unsatisfactory. Systemic therapy has not been successful up to now, with very low response rates to single-agent chemotherapy. Polychemotherapy has increased the response rate (RR), without a significant improvement in overall survival. Immunotherapy alone is able to induce only a few durable complete responses (CRs). New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407508     DOI: 10.1053/sonc.2002.35238

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  38 in total

1.  Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Authors:  J Yan; C Tingey; R Lyde; T C Gorham; D K Choo; A Muthumani; D Myles; L P Weiner; K A Kraynyak; E L Reuschel; T H Finkel; J J Kim; N Y Sardesai; K E Ugen; K Muthumani; D B Weiner
Journal:  Cancer Gene Ther       Date:  2014-11-14       Impact factor: 5.987

2.  Mithramycin A suppresses expression of the human melanoma-associated gene ABCB8.

Authors:  Iwona Sachrajda; Marcin Ratajewski
Journal:  Mol Genet Genomics       Date:  2010-11-03       Impact factor: 3.291

3.  Primary malignant melanoma of left lower lobe of lung: A case report and review of the literature.

Authors:  Xiangwei Zhang; Yang Wang; Jiajun DU
Journal:  Oncol Lett       Date:  2015-05-11       Impact factor: 2.967

4.  Melanoma: Molecular Pathogenesis and Therapeutic Management.

Authors:  Yuxin Liu; M Saeed Sheikh
Journal:  Mol Cell Pharmacol       Date:  2014

Review 5.  Treatment of metastatic malignant melanoma.

Authors:  Ehab Atallah; Lawrence Flaherty
Journal:  Curr Treat Options Oncol       Date:  2005-05

6.  Synergistic Anti-cancer Activity of MH-30 in a Murine Melanoma Model Treated With Cisplatin and its Alleviated Effects Against Cisplatin-induced Toxicity in Mice.

Authors:  Hae-Ran Park; Sung-Kee Jo; Hyang-Hee Cho; Uhee Jung
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

7.  Primary malignant melanoma of the lung with rapid progression.

Authors:  Ryo Maeda; Noritaka Isowa; Hideyuki Onuma; Hiroshi Miura; Hirokazu Tokuyasu; Yuji Kawasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-12

8.  Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis.

Authors:  Laura Ridolfi; Massimiliano Petrini; Laura Fiammenghi; Anna Maria Granato; Valentina Ancarani; Elena Pancisi; Emanuela Scarpi; Massimo Guidoboni; Giuseppe Migliori; Stefano Sanna; Francesca Tauceri; Giorgio Maria Verdecchia; Angela Riccobon; Linda Valmorri; Ruggero Ridolfi
Journal:  Clin Dev Immunol       Date:  2010-09-27

9.  Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism.

Authors:  Ha Kim; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 10.  Chemotherapy in the management of advanced cutaneous malignant melanoma.

Authors:  Jason J Luke; Gary K Schwartz
Journal:  Clin Dermatol       Date:  2013 May-Jun       Impact factor: 3.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.